The American Gastroenterological Association released guidelines on the pharmacological management of irritable bowel syndrome, published in the journal Gastroenterology.
Here are nine things to know from the report.
• Linaclotide in IBS-C. AGA recommends use (strong recommendation, high-quality evidence).
• Lubiprostone in IBS-C. AGA suggests use (conditional recommendation, moderate-quality evidence).
• PEG laxatives in IBS-C. AGA suggests use (conditional recommendation, low-quality evidence).
• Rifaximin in IBS-D. AGA suggests use (conditional recommendation, moderate-quality evidence).
• Alosetron in IBS-D. AGA suggests use (conditional recommendation, moderate-quality evidence).
• Loperamide in IBS-D. AGA suggests use (conditional recommendation, very low-quality evidence).
• Tricyclic antidepressants in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
• Selective serotonin reuptake inhibitors in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
• Antispasmodics in IBS. AGA suggests use (conditional recommendation, low-quality evidence).